Terumo BCT Completes the First Clinical Study Reducing Malaria Transmission from Whole Blood Transfusions with Pathogen Reduction Technology
In low-income countries, 69 percent of collected blood is transfused as whole blood (WB) rather than blood components.1 However, health care professionals have had no proven method to inactivate harmful pathogens and donor white blood cells in WB. This puts patients at risk for contracting diseases and experiencing complications during transfusions. To help advance blood safety, Terumo BCT has recently completed the first and only clinical trial to demonstrate that a pathogen reduction technology—specifically the company’s Mirasol® Pathogen Reduction Technology (PRT) System—can effectively reduce the incidence of transfusion-transmitted infection (TTI) of malaria in WB.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151027006791/en/
Mirasol PRT System (Photo: Business Wire)
Following the success of the Ghana clinical trial, called the African Investigation of Mirasol System (AIMS), Terumo BCT applied for the CE Mark for the Mirasol PRT system for treatment of WB. Prior to this new protocol, blood centers and hospitals in 18 countries across four continents have used the system to treat platelets and plasma.
A safe blood supply is needed for many health care procedures. While low- and middle-income nations account for 82 percent of the world’s population, they collect only approximately half of the blood donations worldwide.2 Furthermore, blood centers in these nations often do not have the latest technologies to test blood extensively for harmful pathogens.
Terumo BCT performed the AIMS trial at Komfo Anokye Teaching Hospital in Kumasi, Ghana. The study tested the ability of the Mirasol PRT system to demonstrate a reduction in TTI of malaria in WB transfusions, which has been demonstrated to occur in up to 28 percent of blood recipients in the region today.3 While no blood safety measure can completely eliminate the risk of TTIs, the subject group in the trial that received Mirasol-treated WB showed a statistically and clinically significant reduction in TTI of malaria compared to the subject group that received untreated WB.4
Additionally, the incidence in the trial of adverse events from the transfused blood products was similar between the treated and untreated groups.
The Mirasol PRT system for treatment of WB demonstrates a new opportunity to advance global blood safety and fight the spread of malaria. Blood centers without the technologies to test blood for harmful pathogens could use this technology to overcome that limitation and reduce the incidence of TTI of malaria in ways never before available.
The Mirasol PRT system for treatment of WB was developed with the support of the U.S. Department of Defense (DoD) through grants and contracts with the U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland. Studies are ongoing to support an application by Terumo BCT to gain U.S. Food and Drug Administration (FDA) approval for the clinical use of red blood cells derived from treated WB. If the application is approved, the Mirasol PRT system will be used in applications such as field hospital settings to support transfusions for military personnel under austere conditions.
- Terumo BCT applied for the CE Mark for the Mirasol PRT system for treatment of WB, and an ongoing clinical study is progressing in the U.S. to evaluate the Mirasol PRT system for red blood cells derived from treated WB
- Terumo BCT recently completed the first and only clinical trial to demonstrate that the Mirasol PRT system can effectively reduce the incidence of TTI of malaria
- No method of testing or pathogen reduction can completely eliminate the risk of a TTI, but the AIMS study showed a clinically and statistically significant reduction of TTI of malaria incidence in the treated group versus the untreated group
- The Mirasol PRT system uses a combination of riboflavin (vitamin B2) and ultraviolet light to inactivate viruses, bacteria, parasites and white blood cells that may be present in collected blood products
- Health care professionals are using the Mirasol PRT system to treat platelets and plasma in more than 70 centers across 18 countries in Europe, the Middle East, South America, Central America and Asia
- The Mirasol PRT system for treatment of WB development program is partially funded by the U.S. Department of Defense
AIMS STUDY METHODOLOGY:
- The AIMS trial was a prospective, randomized, double-blind, controlled, single-center study in which subjects received ≤2 transfusions of either Mirasol-treated fresh whole blood (MIR-WB) or fresh WB prepared by standard-of-care methods
- In the AIMS trial, 223 subjects received trial-related blood transfusions; 111 subjects received MIR-WB and 112 subjects received WB prepared by standard-of-care methods
- Subjects were followed for 28 days post-transfusion
David Perez, President and CEO, Terumo BCT
“Terumo BCT is committed to improving blood safety around the world as a part of our industry promise of ‘Unlocking the potential of blood.’ The need for global blood safety inspired us to complete the AIMS trial, which makes new safety measures available to blood centers. Safer transfusions could translate to less disease, especially for high-risk patient populations like pregnant women, children and trauma victims. Pathogen Reduction Technology through our Mirasol system is one of several initiatives at Terumo BCT to improve blood safety. It is an honor to work in collaboration with our customers to improve patient and clinical outcomes and advance this area of health care.”
Ray Goodrich, PhD, Chief Scientific Officer, Terumo BCT
“The success of the AIMS trial is due to the collaboration of Terumo BCT, Cambridge University, Komfo Anokye Teaching Hospital and the Republic of Ghana. The Mirasol PRT system can enable blood centers to provide safer transfusions despite challenges with access to the blood supply and testing of blood products. This trial is the first to demonstrate significant pathogen reduction in whole blood, marking an important milestone in blood safety.”
Dr. Shirley Owusu-Ofori, Head of the Transfusion Medicine Unit, Komfo Anokye Teaching Hospital
“This clinical trial will provide evidence that may greatly advance the provision of safe blood in Ghana, as well as other developing countries. Terumo BCT's Mirasol PRT system was shown to be effective in this study and has the potential to improve the safety of whole blood. I am hopeful that this system can minimize the residual risk for high-prevalence infections and pathogens, such as malaria, where no screening currently exists that is practical for blood banking in Sub-Saharan Africa.”
About Terumo BCT:
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.
1 Hume H, et al., Chapter 53: “Blood Transfusion in Economically Restricted and Developing Countries,” Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects, 2013, second edition, Elsevier Inc., Amsterdam, Netherlands.
2 World Health Organization, “Blood Safety and Availability,” http://www.who.int/mediacentre/factsheets/fs279/en/, accessed on 11 September 2015.
3 Freimanis G, et al., “Investigating the Prevalence of Transfusion Transmission of Plasmodium within a Hyperendemic Blood Donation System,” Transfusion 2013; 53 (7): 1429–1441.
4 Allain JP, et al., manuscript in preparation.
D.J. Martin, +1-303-239-2060
Global Corporate Communications
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Group Vivendi Africa Deploys Netcracker OSS to Enhance Service Management as it Expands Across the Continent12.12.2017 16:07 | Pressemelding
Netcracker Technology announced today that its OSS suite was selected and deployed to support the long-term growth strategy of Group Vivendi Africa (GVA). GVA is a newly formed affiliate of the French-based multinational conglomerate Vivendi with the goal to deploy and operate a fiber network across Africa. Netcracker's OSS will be used as a consolidated solution to identify service availability across GVA's operating countries and then fulfill and provision those services to customers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005937/en/ Netcracker's highly productized, out-of-the-box applications enabled the OSS suite to be deployed in seven months, meeting GVA's demand to leverage an integrated service fulfillment and inventory solution that could satisfy its long-term growth expectations, as well as s
Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program12.12.2017 15:23 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/ Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire) This issue of the Scientific Update provides a closer look at some of the principles and practices on which PMI’s scientific assessment program is built. Director Medical Affairs Dr. Patrick Picavet describes specific examples from PMI’s clinical program that highlight the company’s
Murex to Offer MX.3 Risk, Trading and Post-Trade Solutions on the AWS Cloud12.12.2017 14:00 | Pressemelding
Murex, an industry leader in trading, risk management and processing solutions for capital markets, announced they will run their MX.3 technology platform on Amazon Web Services, Inc. (AWS). With the acceleration of cloud adoption in capital markets, Murex and AWS agreed to collaborate to help clients migrate their Murex application workloads to the AWS Cloud. Murex clients are looking to consolidate more and more of their capital markets activity on the MX.3 platform and this means their need for infrastructure is increasing. New regulatory requirements are also driving financial organizations to use cloud to scale up their computing capacity. Murex is collaborating with AWS to meet the demand from clients to support deployment of the Murex offering on the AWS Cloud. Murex is working on the validation of a range of deployment scenarios, from using AWS Cloud for bursting grid
Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 13:33 | Pressemelding
Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for
CTS Engines Announces Senior Management Hire12.12.2017 13:00 | Pressemelding
CTS Engines, the global leader for mature jet engine maintenance, announced today that it had hired Diane E. Cavuoto as Senior Vice President, Supply Chain, in an effort to continue to provide its customers with outstanding engine overhaul services. Ms. Cavuoto will be based in CTS’s Ft. Lauderdale headquarters and will report directly to Vesa Paukkeri, CTS’s President and Chief Operating Officer. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005050/en/ Diane E. Cavuoto, Senior Vice President, Supply Chain, for CTS Engines (Photo: Business Wire) Ms. Cavuoto, most recently Vice President, Strategic Sourcing at Honeywell International, brings years of supply chain management experience to CTS. In her prior role at Honeywell, Ms. Cavuoto managed a global commodity team of 150 employees managing $4
MIPI Alliance Opens Access to its MIPI I3C Sensor Interface Specification12.12.2017 13:00 | Pressemelding
The MIPI® Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced it is opening access to its sensor interface specification, MIPI I3C. Starting today, all companies, including those not currently members of MIPI Alliance, may access the MIPI I3C v1.0 specification so they may evaluate the incorporation of the specification into their sensor integration plans and design applications. “MIPI I3C provides a welcome update to the I2C technology that has been widely adopted over the past 35 years. Extending access provides an opportunity to spur innovation and help other industries beyond mobile," said Joel Huloux, chairman of MIPI Alliance. "It helps MIPI members as well, because it supports greater adoption and interoperability, strengthens the ecosystem and provides for a richer
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom